– The global Stem Cell Assay Market is projected to reach US$ 8.5 Bn by 2033, expanding at a CAGR of 16.5% from 2023 to 2033. Attractive demand for stem cell therapies in immune disease, cancer ...

The 13-marker PCR assay developed for this pilot study stemmed from data from a recent study published in Cancer Cell demonstrating the detection of SCLC using DNA methylation in plasma samples ...

FORT MYERS, Fla., May 22, 2025--NeoGenomics announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay.

The VENTANA MET (SP44) RxDx Assay detects the MET (also known as c-Met) protein, which is over-expressed in some patients with non-squamous non-small cell lung cancer (NSQ-NSCLC). The MET protein ...

AUSTIN, Texas-- (BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced data from a colorectal cancer (CRC) study of its tissue-free ...

NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer Provided by Business Wire May 22, 2025, 11:10:00 AM ...